SYS-CON MEDIA Authors: Adine Deford, Cynthia Dunlop, Harry Trott, Xenia von Wedel, Peter Silva

News Feed Item

Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence

SYDNEY, March 4, 2014 /PRNewswire/ -- Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. David W. Gryska, an industry expert with over 20 years of experience in management at many of the top U.S. biotechnology companies, will serve as a strategic advisor to the board with a focus on U.S. capital markets and as a U.S. shareholder liaison.

Novogen Logo. (PRNewsFoto/Novogen Limited)

Prof. Gunning, prime inventor of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and Mr. Ross, will complement existing board members, John P O'Connor BEc., MAICD and Steven Coffey CA. The board appointments are effective March 3, 2014, and reflect the expansion of Novogen in the U.S. while maintaining ties to the company's headquarters in Australia.

"My life's work has focused on researching and developing treatments for children suffering from cancer and believe that, based on early evidence, Novogen's ATM drug platform offers significant potential as a treatment for neuroblastoma, the leading childhood solid cancer, as well as many of the most resilient adult cancers," said Prof. Gunning, who is currently also head of the Oncology Research Unit in the School of Medical Sciences at the University of New South Wales. "I'm pleased to enter into this new role on the board of directors, and to support Novogen as it works towards moving this extremely promising technology into the clinic early next year."

Prof. Gunning has published more than 100 primary research articles and has recently edited the first book devoted to his field of research, Tropomyosin. He previously served as Chair of the Division of Research at The Children's Hospital at Westmead, Chair of the Westmead Research Hub Executive and Chair, Board of Bio-Link, a company established by the New South Wales Government to support commercialization of biomedical intellectual property.

Mr. Ross is currently a non-executive director for ASX-listed companies Benitec Biopharma Ltd. and Tissue Therapies Ltd. Following a career with multinational companies Sandoz AG, Fisons plc, Hoffman La Roche and Celltech Group plc, he has for approximately 20 years undertaken a number of company start-ups, turnarounds and exits as a board member on behalf of private equity groups and banks. These include Quadrant Healthcare PLC (sold to Elan); Eden BioDesign (sold to Watson Pharmaceuticals); Phadia AB – formerly Pharmacia Diagnostics (sold to Cinven); SR Pharma PLC (merged with Atugen AG to form Silence Therapeutics PLC which was then merged with Intradigm Inc); Allergy Therapeutics Limited (prepared for IPO) and Ark Therapeutics PLC (sold subsidiaries off to private equity).

"Throughout my career, it's been a privilege to support companies as they develop promising technology and treatments that can have a real and substantial impact on health," said Mr. Ross. "I hope to bring my broad experience to Novogen to ensure a smooth transition as the company expands its footprint in the U.S. and Australia." 

His track record includes multiple financings transactions, having raised more than £250 million, both publicly and privately, as well as extensive experience of divestments and strategic restructurings and more than 20 years in cross-border management as a chairman and CEO. He has led and participated in four initial public offerings on the London Stock Exchange, and has direct experience of M&A transactions in Europe, the U.S. and Pacific Rim. He is a qualified Chartered Director and Vice Chairman of the Council of Royal Holloway, London University.

Mr. Gryska has more than 20 years of experience in the healthcare space working for companies such as Scios, Johnson & Johnson and Celgene. As a strategic advisor, he brings valuable and relevant experience as a senior financial executive at life sciences and biotechnology companies dealing with financings, mergers, acquisitions, global expansion and other strategic transactions. Mr. Gryska currently serves on the board of directors of four publicly held biotech companies.

Prof. Gunning and Mr. Ross replace Mr. Robert Birch (Non-Executive Director and Deputy Chairman) and Dr. Andrew Heaton (Executive Director).

Robert Birch originally accepted a Board position on the understanding that his role was to help lay the foundations for a successful company and that he would seek to step down once he was satisfied that those foundations were in place. Likewise, Dr. Andrew Heaton also was appointed originally to help steer the Company through its foundation year. Andrew retires in order to focus on his growing role as CEO and President of Novogen North America, and Vice President, Drug Discovery and Manufacture, Novogen Group.

"As we approach the clinic as well as establishing our place in the U.S. biotechnology market, we are pleased to be able to benefit from Peter, Iain and David's substantial biotechnology experience and business acumen," said Graham Kelly, Ph.D., Novogen CEO. "I want to thank Bob Birch and Andrew Heaton for the tremendous work that they have done in helping me rebuild the company. Bob in particular has been a hard-working voice for all Novogen shareholders. Andrew is stepping down for good governance process, with the company now at a position where it needs a non-executive and independent Board, as well as an executive fully focused on a rapidly expanding workload."

About Novogen
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN').  The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.

Further information is available on the Company's website, www.novogen.com

For Further Information Contact: 

Investors

In the USA
David Carey/Tanner Kaufman
Lazar Partners
+1 212-867-1762
[email protected]

In Australia
Rudi Michelson
Monsoon Communications
03 9620 3333
[email protected]

Media

In the USA
Hollister Hovey/Allison Parks
Lazar Partners
+ 1 212-867-1762
[email protected]

In Australia
Dr Douglas Pretsell
Instinctif Partners
+61 (0)3 9657 0706

In ROW
Sue Charles/Stefanie Bacher
Instinctif Partners
+44 (0)20 7457 202

Logo - http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO

SOURCE Novogen Limited

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and ElasticBox held a Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of Bluemix, its services and functionalit...
"We help companies that are using a lot of Software as a Service. We help companies manage and gain visibility into what people are using inside the company and decide to secure them or use standards to lock down or to embrace the adoption of SaaS inside the company," explained Scott Kriz, Co-founder and CEO of Bitium, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's large...
SAP is delivering break-through innovation combined with fantastic user experience powered by the market-leading in-memory technology, SAP HANA. In his General Session at 15th Cloud Expo, Thorsten Leiduck, VP ISVs & Digital Commerce, SAP, discussed how SAP and partners provide cloud and hybrid cloud solutions as well as real-time Big Data offerings that help companies of all sizes and industries run better. SAP launched an application challenge to award the most innovative SAP HANA and SAP HANA...
Want to enable self-service provisioning of application environments in minutes that mirror production? Can you automatically provide rich data with code-level detail back to the developers when issues occur in production? In his session at DevOps Summit, David Tesar, Microsoft Technical Evangelist on Microsoft Azure and DevOps, will discuss how to accomplish this and more utilizing technologies such as Microsoft Azure, Visual Studio online, and Application Insights in this demo-heavy session.
When an enterprise builds a hybrid IaaS cloud connecting its data center to one or more public clouds, security is often a major topic along with the other challenges involved. Security is closely intertwined with the networking choices made for the hybrid cloud. Traditional networking approaches for building a hybrid cloud try to kludge together the enterprise infrastructure with the public cloud. Consequently this approach requires risky, deep "surgery" including changes to firewalls, subnets...
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water,...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happe...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!